Cervical Cancer
Why trials studying Cervical Cancer stopped, in this sample of ClinicalTrials.gov.
21 stopped trials with a clear reason; 90% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| slow accrual | 10 | 48% |
| funding business | 6 | 29% |
| logistics pi | 1 | 5% |
| futility | 1 | 5% |
| regulatory | 1 | 5% |
| manufacturing supply | 1 | 5% |
| other | 1 | 5% |
Trials
- Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
NCT07211204 · WITHDRAWN · regulatory
“The study did not start, i.e., no participants were enrolled, because the Mexican Regulatory Authority (COFEPRIS) did not authorize the amendments to the protocol.” - Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
NCT06099418 · WITHDRAWN · funding business
“Trial VB-C-04 was stopped due to company strategic reasons and recent changes in standard of care in the recurrent and metastatic cervical cancer setting.” - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
NCT06022757 · TERMINATED · funding business
“Strategic decision by Sponsor.” - Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women in Cleveland
NCT05470309 · WITHDRAWN · logistics pi
“Personnel departure.” - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
NCT04116320 · TERMINATED · slow accrual
“Unable to enroll enough patients to complete targeted enrollment in a reasonable time.” - OCT-AF Imaging of Pre-cancers of Vulva and Cervix
NCT03285841 · TERMINATED · funding business
“No funding” - Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
NCT04234113 · TERMINATED · futility
“Due to lack of efficacy shown at the time of the interim analysis.” - Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
NCT04106167 · TERMINATED · funding business
“This study was terminated by the Sponsor.” - RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
NCT03894215 · TERMINATED · funding business
“Sponsor strategic decision” - Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
NCT03644459 · WITHDRAWN · slow accrual
“Unable to recruit individuals for the study” - A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
NCT03829501 · TERMINATED · funding business
“Early discontinuation based on strategic sponsor decision not driven by any safety concerns.” - Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility
NCT03852979 · TERMINATED · other
“study is merged with CONTESSA study” - Ultrasound and Photoacoustic Imaging for Cervical Cancer
NCT03318107 · TERMINATED · slow accrual
“Low accrual” - Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB
NCT03146039 · WITHDRAWN · slow accrual
“Patient enrollment goal will not be met” - GSK1120212+GSK2141795 for Cervical Cancer
NCT01958112 · TERMINATED · manufacturing supply
“Drug supply” - CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
NCT01583686 · TERMINATED · slow accrual
“Study terminated due to slow/insufficient accrual.” - Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer
NCT00967928 · WITHDRAWN · slow accrual
“Lack of enrollment” - Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
NCT00428194 · WITHDRAWN · slow accrual
“Withdrawn due to lack of accrual” - Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer
NCT00118300 · WITHDRAWN · slow accrual
“Competing studies” - Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix
NCT00084890 · TERMINATED · slow accrual
“slow accrual” - Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer
NCT00138151 · TERMINATED · slow accrual
“Slow accrual and lack of study drug”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.